Thank you.
Mr. Chair, I think we are at a turning point, for sure, given the supply. The vast majority of vaccines will be the Pfizer vaccine. Having a diverse portfolio as a backup option is always a good idea.
With the AstraZeneca vaccine, the provinces and territories have chosen to pause giving any more new first doses. We do, however, need additional supplies, which we have, for the second dose for people who wish to take the AstraZeneca because they started on that schedule.
As you probably appreciate, there are data that we are still looking at on the mixed schedule. The National Advisory Committee on Immunization, once they have that data, will be able to provide a recommendation to determine whether the mRNA vaccines, such as Pfizer, are suitable for that second dose.
After that, there still need to be some backup options for people who might be allergic to mRNA vaccines or who for some other reason can't take them. It's still important to have some diversification in our approach.